Resources for Patients and Caregivers
Hallucinations are where someone sees, hears, smells, tastes or feels things that don’t exist outside their mind. They’re common in people with schizophrenia, and are usually experienced as hearing voices. Hallucinations can be frightening, but there’s usually an identifiable cause.
Wiki Number: 22-Hallucinations
US Patients: 10-15% over a lifetime of even healthy individuals
Symptoms: perceptions of external stimuli which do not exist
Progression: can occur through any of the senses
Causes: occur frequently in schizophrenia, parkinson’s disease. More than five cups of coffee.
Resources for Physicians, Counselors and Researchers
4 CURRENT ARTICLES
The world-wide medical research
reports chosen for each diagnosis
Clicking each title opens the
PubMed article’s summary-abstract.
- An Exploration of Subgroups of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Their Risks of Conversion to Dementia or Deathby Jiayue Qiu on January 24, 2022
CONCLUSION: Our findings of three NPS subgroups in MCI characterized by affect, hyperactive, or psychotic features are largely consistent with a previous 3-factor model of NPS found in a demented population. The consistency of these findings across studies and samples, coupled with our results on the associated risks of converting to dementia, suggests that the NPS structure is robust, and warrants further consideration in classification models of MCI.
- Measurement invariance between online and paper-and-pencil formats of the Launay-Slade Hallucinations scale-extended (LSHS-E) in the Chilean population: Invariance between LSHS-E formatsby Yanet Quijada on January 24, 2022
Research on the multidimensionality of hallucination-like experiences (HLEs) can contribute to the study of psychotic risk. The Launay-Slade Hallucinations Scale-Extended (LSHS-E) is one of the most widely used tools for research in HLEs, but the correspondence of its paper and online formats has not been established yet. Therefore, we studied the factorial structure and measurement invariance between online and paper-and-pencil versions of LSHS-E in a Chilean population. Two thousand eighty-six...
- A phase 1b open-label dose-finding study of ustekinumab in young adults with type 1 diabetesby Ashish K Marwaha on January 24, 2022
CONCLUSION: Ustekinumab was deemed safe to progress to efficacy studies by the DSMB at doses used to treat psoriasis in adults with T1D. A 90 mg maintenance dosing schedule reduced proinsulin-specific IFN-γ and IL-17A-producing T cells. Further studies are warranted to determine if ustekinumab can prevent C-peptide AUC decline and induce a clinical response.
- Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic databy Carla Abdelnour on January 22, 2022
CONCLUSIONS: This study demonstrates that there are subgroups of DLB patients with different biological, clinical, and demographic characteristics. These findings may have implications in the diagnosis and prognosis of DLB, as well as in the treatment response in clinical trials.